Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens.
about
Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infectionsRole of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae.Pharmacokinetic-Pharmacodynamic Target Attainment Analyses to Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Cystic Fibrosis.Ceftazidime-avibactam: novel antimicrobial combination for the treatment of complicated urinary tract infections.Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy.Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.In vitro pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms.A programme to create short-course chemotherapy for pulmonary Mycobacterium avium disease based on pharmacokinetics/pharmacodynamics and mathematical forecasting.A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease.The discovery of ceftazidime/avibactam as an anti-Mycobacterium avium agent.Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-lactamase Inhibitor, Dosed in Combination with Imipenem/Cilastatin in Healthy Subjects.Validation of a Model Predicting Anti-infective Lung Penetration in the Epithelial Lining Fluid of Humans.Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections.
P2860
Q28069563-569E3676-AD05-4C0D-BE24-5949551646B0Q33816251-20BF9558-3E1B-4851-9AAF-64A7604B126CQ38636242-1DE85DD7-44E0-4CC8-AB7F-4861A43C8556Q38740494-99384164-4482-46EA-872C-3A4AFC323B48Q38944862-B1455828-92D2-43B7-A163-B0F21B5CD496Q39183212-1709CC28-28FD-4DDB-B67D-40BD22A53BE3Q40065397-27EB3526-DC40-4BF3-95FF-199AE2225D52Q40702364-8339175B-6194-402B-80B4-38DF067C01FFQ41996871-13AC85FA-4E13-4270-9663-EA25EEF1B48AQ41996885-B4A0BBF4-BFC6-412C-AC34-05E7E442C843Q41996889-B6A78E58-93D0-4BD9-AF10-47FDB008E62AQ46267269-140A61C8-A9F5-45A9-BA09-DFF6C90AD3C8Q47195583-76892199-DB4A-46D6-9C35-72275ACB46FDQ49721058-28576578-BC48-4D05-9575-CD8988DF1169Q52673296-79711E96-EAAE-4F48-9D3E-948F322389CB
P2860
Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Phase 1 study assessing the st ...... following two dosing regimens.
@en
Phase 1 study assessing the st ...... following two dosing regimens.
@nl
type
label
Phase 1 study assessing the st ...... following two dosing regimens.
@en
Phase 1 study assessing the st ...... following two dosing regimens.
@nl
prefLabel
Phase 1 study assessing the st ...... following two dosing regimens.
@en
Phase 1 study assessing the st ...... following two dosing regimens.
@nl
P2093
P2860
P356
P1476
Phase 1 study assessing the st ...... following two dosing regimens
@en
P2093
David P Nicolau
Jon Armstrong
Maria Learoyd
Timi Edeki
P2860
P304
P356
10.1093/JAC/DKV170
P407
P577
2015-07-01T00:00:00Z